$CNSP News

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

CNS Pharmaceuticals Q1 EPS $(7.30) Misses $(5.37) Estimate

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals Enters Securities Purchase Agreements For ~$22.5M Private Placement Of 650,000 Shares At $2.30 Per Share And Warrants To Purchase Up To ~9.1M Shares At Purchase Price $2.299 Per Warrant

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

CNS Pharmaceuticals Launches Global Search For Neurology And Oncology Assets, Shifts Focus From Glioblastoma

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation

CNS Pharmaceuticals Appoints Steve O'Loughlin CFO, Effective March 2, Succeeding Christopher Downs

CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals' New CEO Rami Levin Outlines Strategic Focus On Pipeline Optimization And Value Creation

CNS Pharmaceuticals' New CEO Rami Levin Outlines Strategic Focus On Pipeline Optimization And Value Creation

CNS Pharmaceuticals Announces CEO Transition

CNS Pharmaceuticals Appoints Rami Levin CEO, Succeeding John Climaco

CNS Pharmaceuticals CEO John Climaco Steps Down, Rami Levin Named New Chief Executive

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update